bazedoxifene has been researched along with reparixin in 1 studies
| Studies (bazedoxifene) | Trials (bazedoxifene) | Recent Studies (post-2010) (bazedoxifene) | Studies (reparixin) | Trials (reparixin) | Recent Studies (post-2010) (reparixin) |
|---|---|---|---|---|---|
| 307 | 69 | 249 | 70 | 4 | 48 |
| Protein | Taxonomy | bazedoxifene (IC50) | reparixin (IC50) |
|---|---|---|---|
| C-X-C chemokine receptor type 1 | Homo sapiens (human) | 0.0031 | |
| C-X-C chemokine receptor type 2 | Homo sapiens (human) | 0.0354 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, S; Lin, J | 1 |
1 other study(ies) available for bazedoxifene and reparixin
| Article | Year |
|---|---|
Blocking Interleukin-6 and Interleukin-8 Signaling Inhibits Cell Viability, Colony-forming Activity, and Cell Migration in Human Triple-negative Breast Cancer and Pancreatic Cancer Cells.
Topics: Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclobutanes; Drug Synergism; Female; Humans; Indoles; Interleukin-6; Interleukin-8; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Sulfonamides; Triple Negative Breast Neoplasms | 2018 |